P1154: EFFICACY OF SUBCUTANEOUS EPCORITAMAB VS AXI-CEL IN R/R DLBCL CAR T-NAIVE AND CAR T-ELIGIBLE PATIENTS: AN INDIRECT COMPARISON

• Catherine Thieblemont,
• Christopher Fox,
• Anthony Wang,
• Kavita Sail,
• Abualbishr Alshreef,
• Michael Moran,
• Alex Mutebi,
• Julie Blaedel,
• Viktor Chirikov,
• Gilles Salles

Affiliations

Catherine Thieblemont

1 Assistance Publique & Hôpitaux de Paris (APHP), Hôpital Saint-Louis, Hémato-oncologie, Université de Paris, Paris, France

Christopher Fox

2 Department of Haematology, Nottingham City Hospital, Nottingham University Hospitals NHS Trust, Nottingham, United States

Anthony Wang

3 AbbVie, Inc., North Chicago, IL, United States

Kavita Sail

3 AbbVie, Inc., North Chicago, IL, United States

Abualbishr Alshreef

3 AbbVie, Inc., North Chicago, IL, United States

Michael Moran

3 AbbVie, Inc., North Chicago, IL, United States

Alex Mutebi

4 Genmab US Inc., Plainsboro, NJ, United States

Julie Blaedel

4 Genmab US Inc., Plainsboro, NJ, United States

Viktor Chirikov

5 OPEN Health, Bethesda, MD, United States

Gilles Salles

6 Memorial Sloan Kettering Cancer Center, New York, NY, United States